Day: November 5, 2021

PAOLI, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) — Malvern Bancorp, Inc. (the “Company”) (Nasdaq: MLVF), the holding company for Malvern Bank, National Association (the “Bank”), announced that it completed a sale to a single investor of certain problem loans. Specifically, the Company sold three loans with a book balance of $29.3 million with a write down of approximately $10.4 million. The loans sold included approximately $12.2 million of non-accruing loans and $17.1 million of performing troubled debt restructurings. The Company has classified the loans as “held for sale” at September 30, 2021, after taking write downs to reflect the anticipated sale price of such loans. Including the write down, the Company expects to record a provision for loan and lease losses of approximately $10.6 million at the quarter ended September 30, 2021....

Los Angeles, CA., Nov. 05, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, announced today that it will host a virtual-only shareholder update call on November 9, 2021 at 2:30PM MST / 4:30PM EST. The shareholder update call will be facilitated by Draganfly CEO, Cameron Chell, who will review the Company’s milestones; and CFO Paul Sun, who will review the Company’s financial results for Q3 2021, which are planned to be filed after market on November 9, 2021. Draganfly President, Scott Larson will be facilitating pre-submitted and live chat questions and answers. Registration for the call can be done here. The Company will answer pre-submitted questions at the conclusion of prepared remarks. Investors...

The successful procedure, performed by Golden Grand and broadcasted live on Chinese TV, will support the Company’s campaign to obtain additional licensing and sale agreements world-wide. Golden Grand payments to Medigus to total $2.4 million Tel Aviv, Israel, Nov. 05, 2021 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that it has achieved an additional milestone as part of its licensing and sale agreement with Golden Grand (Shanghai Golden Grand-Medical Instruments Ltd.) for the use and sale of Medigus’ FDA approved MUSE™ system in China, Hong Kong, Taiwan and Macao. Golden Grand informed the Company of the completion of a successful procedure using the MUSE™ system...

TORONTO, Nov. 05, 2021 (GLOBE NEWSWIRE) — Gowest Gold Ltd. (“Gowest” or the “Company”) (TSX VENTURE: GWA) announced today that it has entered into a loan agreement with Lush Land Investment Canada Inc.(“Lush Land”) in respect of a bridge loan in the principal amount of $1,000,000 for working capital. The loan matures on October 31, 2022. Interest on the outstanding principal balance shall accrue daily and be calculated, in arrears, at the rate of 10% per annum. The bridge loan may be repaid at any time prior to maturity without penalty. Meirong Yuan, a director of Gowest, holds 25% of Lush Land. Noted Dan Gagnon, Gowest’s President and Chief Executive Officer, “This loan is assisting us as we finalize our review of the revised mining and exploration plans, all in preparation for a near-term restart of operations at our wholly-owned...

Prestigious annual award recognizes the best in real estate development projects across New York City SL Green applauded for providing public infrastructure benefits that transformed the civic experience in and around Grand Central Terminal NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that it was awarded the 2021 Urban Land Institute’s New York Award for Excellence in Development for One Vanderbilt under the “Office Development” category. Through its Global Awards for Excellence, the Urban Land Institute’s prestigious awards program honors best-in-class development that reflects the responsible land use practice and creation of sustainable, thriving communities. One Vanderbilt, the skyline-defining tower designed by world-renowned architecture...

Company announcement – No. 66/ 2021 Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)Agreement grants Zealand a worldwide, exclusive license to use DEKA’s continuous infusion pump for the potential treatment of CHI with dasiglucagon DEKA will be responsible for pump development and manufacturing Zealand will be responsible for clinical development of the drug-device combination and commercialization in all territoriesCopenhagen, DK and Boston, MA, U.S. November 05, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that it has...

SANTA CLARA, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — Applied Materials, Inc. will hold a webcast to discuss its fourth quarter and fiscal 2021 financial results on Thursday, Nov. 18, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast will be accessible via the Applied Materials website at: https://ir.appliedmaterials.com. A replay will be available on the same day beginning at 8:00 p.m. ET / 5:00 p.m. PT. About Applied MaterialsApplied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible a better future. Learn more at www.appliedmaterials.com. Contact:Ricky...

CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Atlanta, GA and virtually from December 11-14, 2021. “As we continue to advance our full-spectrum strategy, we look forward to sharing preclinical data from our ex vivo platform with the research community at this year’s ASH Annual Meeting,” said Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. “The data will feature our novel allogeneic technology designed to overcome...

Expects to sanction approximately $7 billion of new capital projects in 2021Modified dividend growth outlook enhances ability to fund substantial new growth opportunities CALGARY, Alberta, Nov. 05, 2021 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) today announced net income attributable to common shares for third quarter 2021 of $779 million or $0.80 per share compared to net income of $904 million or $0.96 per share for the same period in 2020. Comparable earnings for third quarter 2021 were $1.0 billion or $0.99 per common share compared to $893 million or $0.95 per common share in 2020. TC Energy’s Board of Directors also declared a quarterly dividend of $0.87 per common share for the quarter ending December 31, 2021, equivalent to $3.48 per common share on an annualized basis. “During...

Achiko to develop dengue fever diagnostic test by applying its DNA aptamer technology platform. This is another promising application of the technology that Achiko is already successfully using to diagnose Covid-19. The dengue virus infects about 400 million people every year and is endemic to where 3.6 billion (40%) of the world’s population live. Achiko is developing a range of diagnostic tests for other pathogenic diseases applying DNA aptamer technology.ZURICH, Switzerland, Nov. 05, 2021 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) a global healthtech company currently developing technologies that seek to deliver rapid, affordable diagnostic testing for Covid-19 and a range of other pathogenic diseases announced today the development of...